hosted by

Edouard de Dreuzy

Institut des Maladies Emergentes et Thérapies Innovantes (iMETI)

Service des Thérapies Innovantes - Inserm U962

Commissariat à l'énergie atomique

Centre de Fontenay-aux-Roses
18, route du Panorama - BP6
92265 Fontenay aux Roses Cedex, France
Edouard de Dreuzy

---| March 2016 - Today
Genethon/INTEGRARE Blood and Immune Diseases Program

---| September 2011 – February 2016
PhD Student at CEA -- Institute of emerging diseases and innovative therapy (iMETI)
Inserm U962 - Fontenay-aux-Roses
Gene and Cell therapy Laboratory

-Effect of the insertional activation of HMGA2 by lentiviral vectors in the context of the clinical trial "LentiGlobin".
-Development of novel targeting strategies for gene therapy.

---| April 2011 – september 2011 : Research assistant Intern
GlaxoSmithKline, Stevenage (United Kingdom)

-Epigenetic target validation for immuno-inflammatory diseases.
-Hit compounds testing by cell biology assays.

---| September 2009 – February 2010 : Research assistant Intern
Genethon, Evry (France)

- Physiopathology of dysferlinopathy : Observation of membrane tears in mice skeletal muscle fibers during excentric contractions by in vivo confocal imaging with fluorescence
- Development of a cell membrane repair test to assess the functionality of dysferlin after gene therapy
- Development of a calcium imaging technique on isolated skeletal muscle fibers
Powered by